Apeloa Pharmaceutical Co.,Ltd (SHE:000739)
China flag China · Delayed Price · Currency is CNY
18.23
+0.39 (2.19%)
Feb 3, 2026, 11:34 AM CST

SHE:000739 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Jan '23 Jan '22 Dec '20
Operating Revenue
10,43011,95711,44010,5068,9107,852
Other Revenue
65.3565.3533.9239.132.4428.09
10,49612,02211,47410,5458,9437,880
Revenue Growth (YoY)
-14.42%4.77%8.81%17.92%13.49%9.28%
Cost of Revenue
8,0079,2258,6218,0756,5795,700
Gross Profit
2,4882,7962,8532,4702,3642,179
Selling, General & Admin
1,0531,1211,125985.33906.43957.56
Research & Development
639.28641.47624.87532.92446.22350.06
Other Operating Expenses
42.412.7623.331.7633.0538.83
Operating Expenses
1,7311,7851,7751,5631,4051,356
Operating Income
757.541,0121,078906.8959.39823.59
Interest Expense
-26.14-32.2-43.77-59.23-35.72-16.01
Interest & Investment Income
115.5692.17113.4775.83165.786.9
Currency Exchange Gain (Loss)
58.3858.3838.1393.42-23.09-73.61
Other Non Operating Income (Expenses)
21.242.21-23.85-5.38-3.58-2.33
EBT Excluding Unusual Items
926.581,1321,1621,0111,063818.54
Gain (Loss) on Sale of Investments
-10.45-10.13-21.7-82.61-23.6247.45
Gain (Loss) on Sale of Assets
0.80.281.331.370.288.52
Asset Writedown
16.43-8.4--4.67-7.95-10.2
Other Unusual Items
89.2289.2263.2386.5282.6796.85
Pretax Income
1,0231,2031,2051,0121,114961.15
Income Tax Expense
160.94172.44149.3422.89158.53144.42
Earnings From Continuing Operations
861.651,0311,055989.17955.55816.73
Minority Interest in Earnings
0.090.270.030--
Net Income
861.741,0311,055989.17955.55816.73
Net Income to Common
861.741,0311,055989.17955.55816.73
Net Income Growth
-19.74%-2.30%6.69%3.52%17.00%47.58%
Shares Outstanding (Basic)
1,1561,1631,1691,1741,1791,179
Shares Outstanding (Diluted)
1,1561,1631,1691,1741,1791,179
Shares Change (YoY)
-0.87%-0.52%-0.40%-0.38%-0.00%0.01%
EPS (Basic)
0.750.890.900.840.810.69
EPS (Diluted)
0.750.890.900.840.810.69
EPS Growth
-19.04%-1.78%7.12%3.91%17.00%47.57%
Free Cash Flow
507.66748.01400.9817-90.18742.41
Free Cash Flow Per Share
0.440.640.340.70-0.080.63
Dividend Per Share
0.7040.3560.3170.2970.2850.243
Dividend Growth
122.27%12.35%6.70%4.21%17.28%47.27%
Gross Margin
23.71%23.26%24.86%23.42%26.43%27.66%
Operating Margin
7.22%8.42%9.39%8.60%10.73%10.45%
Profit Margin
8.21%8.58%9.20%9.38%10.69%10.37%
Free Cash Flow Margin
4.84%6.22%3.49%7.75%-1.01%9.42%
EBITDA
1,3301,5761,6311,2961,3181,168
EBITDA Margin
12.67%13.11%14.21%12.29%14.74%14.82%
D&A For EBITDA
572.15563.97553.06389.43358.64344.06
EBIT
757.541,0121,078906.8959.39823.59
EBIT Margin
7.22%8.42%9.39%8.60%10.73%10.45%
Effective Tax Rate
15.74%14.33%12.40%2.26%14.23%15.03%
Revenue as Reported
10,49612,02211,47410,5458,9437,880
Advertising Expenses
-11.299.671.611.862.96
Source: S&P Global Market Intelligence. Standard template. Financial Sources.